Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sutro Biopharma (STRO) FCF Margin (2017 - 2025)

Sutro Biopharma (STRO) has disclosed FCF Margin for 9 consecutive years, with 377.8% as the latest value for Q4 2025.

  • Quarterly FCF Margin rose 11383.0% to 377.8% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 206.73% through Dec 2025, up 15280.0% year-over-year, with the annual reading at 172.95% for FY2025, 14077.0% up from the prior year.
  • FCF Margin hit 377.8% in Q4 2025 for Sutro Biopharma, up from 409.34% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 245.58% in Q3 2022 to a low of 1211.53% in Q1 2025.
  • Historically, FCF Margin has averaged 313.66% across 5 years, with a median of 306.43% in 2023.
  • Biggest five-year swings in FCF Margin: skyrocketed 46610bps in 2022 and later plummeted -71214bps in 2025.
  • Year by year, FCF Margin stood at 326.06% in 2021, then increased by 3bps to 315.47% in 2022, then skyrocketed by 104bps to 11.11% in 2023, then crashed by -4526bps to 491.63% in 2024, then rose by 23bps to 377.8% in 2025.
  • Business Quant data shows FCF Margin for STRO at 377.8% in Q4 2025, 409.34% in Q3 2025, and 68.36% in Q2 2025.